A peptide's half-life is often quoted as a single number. On its own, that number is incomplete: half of what, measured where, under which conditions? A biological half-life describes change over time in a defined system. It is not a universal lifetime printed into the molecule's sequence.
Ask which quantity has fallen by half
An elimination half-life refers to the time for plasma concentration to fall by 50% during the elimination phase. The phase qualification matters: a concentration–time curve can reflect more than one process. A laboratory degradation half-life in an isolated biological sample is a different measurement.Guilding and colleagues — Core concepts of pharmacology: a global initiative (opens in a new tab)
Read the noun attached to the measurement. Intact peptide, total immunoreactive material and a labelled signal need not describe the same molecular population. If the method detects several forms together, the curve cannot automatically be described as the disappearance of only the intact form.
| Field | What to recover |
|---|---|
| Species | Intact molecule or another defined signal |
| Setting | Organism, compartment or isolated sample |
| Conditions | Experimental state and relevant interventions |
| Model | The fitted phase and assumptions |
Understand repeated halving with a simple model
For first-order decline under constant conditions, a constant fraction is lost over a given interval. An illustrative half-life of 20 minutes would take a normalised amount from 100 to 50 after 20 minutes, to 25 after 40 minutes and to 12.5 after 60 minutes. This is a hypothetical model, not a result for a named peptide.IUPHAR — Clinical pharmacokinetics (opens in a new tab)
The amount lost in each interval becomes smaller: 50, then 25, then 12.5 units. This differs from subtracting a fixed 50 units every 20 minutes. It also explains why two half-lives do not mean that every molecule has disappeared.
The calculation assumes no new input and the same first-order process throughout. If those assumptions do not match the experiment, repeating the halving pattern is not a justified prediction.
Experimental conditions can change the result
Deacon and colleagues studied intact GLP-1 in anaesthetised pigs and reported a longer plasma half-life when DPP IV activity was inhibited. This provides a concrete example of a half-life depending on the biological conditions. It does not supply a half-life for a different peptide, an untested preparation or human use.Deacon and colleagues — DPP IV inhibition and GLP-1 in the anaesthetised pig (opens in a new tab)
When two papers report different values, compare their definitions and conditions before choosing one. They may follow different molecular forms, species, sample matrices or portions of a concentration–time curve. A disagreement in numbers is not enough to establish a contradiction.
A useful comparison table keeps those fields beside the value. Avoid selecting the longest result simply because it appears favourable, or averaging incompatible half-lives into a supposedly representative number.
Separate disappearance from effect and shelf life
A concentration curve and a response curve measure different quantities. A concentration half-life therefore cannot, by itself, tell you the duration of every downstream response. That would require a demonstrated relationship between exposure and the endpoint being discussed.
Storage expiry concerns whether a supplied material continues to meet defined requirements under specified storage conditions. A biological experiment involving enzymes, cells or an organism does not answer that storage question. The word stability can refer to either setting, so check how the authors use it.
Preserve the uncertainty in your summary
- Keep the reported value, units and uncertainty together.
- Identify the measured molecular form and biological setting.
- Distinguish a fitted elimination phase from another kind of decay experiment.
- State when the source does not provide enough detail for a comparison.
Sources and further detail
- Guilding and colleagues — Core concepts of pharmacology: a global initiative (opens in a new tab)
British Journal of Pharmacology 181, 375–392 (2024), DOI 10.1111/bph.16222. Table 2, including corrected affinity statement 6.3.
- IUPHAR — Clinical pharmacokinetics (opens in a new tab)
Concentration–time relationships and the difference between first-order and zero-order change. Clinical administration examples are outside this article's scope.
- Deacon and colleagues — DPP IV inhibition and GLP-1 in the anaesthetised pig (opens in a new tab)
Diabetes 47, 764–769 (1998), DOI 10.2337/diabetes.47.5.764. The abstract reports a condition-dependent change in intact-peptide plasma half-life; no rate is extrapolated to people or products.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.